Current Edition


That key Gilead breast cancer readout? Try 2024, and don’t get your hopes up: analyst

Gilead Sciences just tipped off what sounded like mixed results for Trodelvy, the cornerstone of the Big Biotech’s oncology ambitions. Now, one analyst suggests investors …

Continue Reading →

Gilead drops unclear win for key Trodelvy breast cancer trial, poking holes in CEO’s oncology plan

Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath …

Continue Reading →